Sparsomycin is a nucleotide analogue produced by Streptomyces sparsogenes isolated by researchers at Upjohn (now Pfizer) in 1962. Sparsomycin binds to the 50S ribosomal subunit and inhibits protein synthesis via peptidyl transferase inhibition. Sparsomycin is very active against κβ human epidermoid carcinoma cells in tissue cultures and moderately active against Gram-positive and Gram-negative bacteria and fungi. The biosynthesis of Sparsomycin has been extensively studied.
Ermolenko D.N (2013) Antibiotics that bind to the A site of the large ribosomal subunit can induce mRNA translocation. et al. 19:158
Owen SP et al (1962) Sparsomycin, a new antitumor antibiotic. I. Discovery and biological properties. Owen S.P. et al., Antimicrob.Agents Chemother. 772
Parry RJ and Eudy ME (1988) The biosynthesis of sparsomycin. Elucidation of the origins of the carbon skeleton. J. Am. Chem. Soc. 110:2316